MA50264B1 - Méthodes de traitement des infections de type hépatite b - Google Patents

Méthodes de traitement des infections de type hépatite b

Info

Publication number
MA50264B1
MA50264B1 MA50264A MA50264A MA50264B1 MA 50264 B1 MA50264 B1 MA 50264B1 MA 50264 A MA50264 A MA 50264A MA 50264 A MA50264 A MA 50264A MA 50264 B1 MA50264 B1 MA 50264B1
Authority
MA
Morocco
Prior art keywords
methods
treating hepatitis
type infections
infections
type
Prior art date
Application number
MA50264A
Other languages
English (en)
Other versions
MA50264A (fr
Inventor
Martin Koser
Marc Abrams
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66173915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50264(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of MA50264A publication Critical patent/MA50264A/fr
Publication of MA50264B1 publication Critical patent/MA50264B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Abstract

Cette invention concerne de puissants oligonucléotides utiles pour réduire l'expression de hbsag et traiter des infections par le vhb.
MA50264A 2017-10-20 2018-10-19 Méthodes de traitement des infections de type hépatite b MA50264B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762575358P 2017-10-20 2017-10-20
PCT/US2018/056801 WO2019079781A2 (fr) 2017-10-20 2018-10-19 Méthodes de traitement des infections de type hépatite b

Publications (2)

Publication Number Publication Date
MA50264A MA50264A (fr) 2020-07-29
MA50264B1 true MA50264B1 (fr) 2023-03-31

Family

ID=66173915

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50264A MA50264B1 (fr) 2017-10-20 2018-10-19 Méthodes de traitement des infections de type hépatite b

Country Status (28)

Country Link
US (5) US10799524B2 (fr)
EP (2) EP4197544A1 (fr)
JP (2) JP7353276B2 (fr)
KR (1) KR20200083494A (fr)
CN (1) CN111372593B (fr)
AU (1) AU2018351649A1 (fr)
BR (1) BR112020007476A2 (fr)
CA (1) CA3078960A1 (fr)
CL (1) CL2020001061A1 (fr)
CO (1) CO2020005135A2 (fr)
CR (1) CR20200163A (fr)
DK (1) DK3684377T3 (fr)
ES (1) ES2936863T3 (fr)
FI (1) FI3684377T3 (fr)
HR (1) HRP20230023T1 (fr)
HU (1) HUE061122T2 (fr)
IL (2) IL274040B1 (fr)
LT (1) LT3684377T (fr)
MA (1) MA50264B1 (fr)
MX (1) MX2020004060A (fr)
PE (1) PE20220561A1 (fr)
PH (1) PH12020550591A1 (fr)
PL (1) PL3684377T3 (fr)
PT (1) PT3684377T (fr)
RS (1) RS64001B1 (fr)
SG (1) SG11202003488WA (fr)
SI (1) SI3684377T1 (fr)
WO (1) WO2019079781A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7353276B2 (ja) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎感染の治療方法
WO2021067744A1 (fr) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Modifications chimiques de petits arn interférents avec une teneur minimale en fluor
CN114867856A (zh) * 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
MX2022007908A (es) * 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
WO2022026387A1 (fr) * 2020-07-27 2022-02-03 Aligos Therapeutics, Inc. Oligonucléotides de liaison au vhb et méthodes d'utilisation
IL300340A (en) 2020-08-05 2023-04-01 Hoffmann La Roche Treatment with oligonucleotides in hepatitis B patients
CN114940991B (zh) * 2021-04-13 2023-02-03 厦门甘宝利生物医药有限公司 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用
WO2022223515A2 (fr) * 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions et procédés pour inhiber l'expression de l'élément 3 du groupe h de la sous-famille 1 de récepteur nucléaire (nr1h3)
WO2023083906A2 (fr) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Combinaisons pharmaceutiques pour le traitement du vhb
CA3235672A1 (fr) * 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions et procedes d'inhibition de l'expression de la proteine du virus de l'hepatite b (hbv)
EP4201947A1 (fr) 2021-12-22 2023-06-28 F. Hoffmann-La Roche AG Procédé de déprotection de squelette d'oligonucléotides contenant un groupe d'alkylephosphonate terminal
WO2023116764A1 (fr) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 Acide nucléique, composition et conjugué le contenant, et utilisation de celui-ci, de la composition et du conjugué

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
JP4095895B2 (ja) 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (fr) 2001-11-07 2003-05-15 Applera Corporation Nucleotides universels pour analyse d'acides nucleiques
EP2314691A3 (fr) 2002-11-14 2012-01-18 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (fr) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification de molecules d'acide ribonucleique bicatenaire
EP1979485A2 (fr) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation
DK2094086T3 (da) * 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
CN101755049B (zh) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 初级微rna表达盒
ES2708944T3 (es) 2008-09-22 2019-04-12 Dicerna Pharmaceuticals Inc Composiciones y métodos para la inhibición específica de la expresión de genes por DSRNA que tenga modificaciones
EP3067359A1 (fr) 2008-09-23 2016-09-14 Scott G. Petersen Pro-oligomères protégés par phosphate biolabiles auto-administrés pour agents thérapeutiques à base d'oligonucléotide et médiation d'arn interférence
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CA3151965A1 (fr) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Agents allonges servant de substrats de dicer et procedes d'inhibition specifique de l'expression d'un gene
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
EA201290152A1 (ru) * 2009-10-16 2012-12-28 Глаксо Груп Лимитед Антисмысловые ингибиторы вируса гепатита в (hbv)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
KR102072631B1 (ko) * 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
RU2667524C2 (ru) * 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита b (hbv)
CN113430196A (zh) * 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
WO2013063313A1 (fr) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de gccr
AU2013356383B2 (en) 2012-12-06 2017-08-31 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
TW201437368A (zh) * 2012-12-14 2014-10-01 Dicerna Pharmaceuticals Inc 藉由雙股ｒｎａ之ｃｋａｐ５之專一性抑制之方法和組成物
CN103333890B (zh) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US20170114341A1 (en) 2014-06-06 2017-04-27 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
WO2016030863A1 (fr) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Composés et méthodes de traitement des infections virales
JOP20200092A1 (ar) * 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3865576A1 (fr) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Acides nucléiques double brin modifiés par un ligand
WO2016183009A2 (fr) * 2015-05-08 2016-11-17 Dicerna Pharmaceuticals, Inc. Méthodes et compositions pour l'inhibition spécifique de l'antithrombine 3 (at3) par un arn bicaténaire
CA2991639A1 (fr) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Therapie par interference arn pour l'infection par le virus de l'hepatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
JP7353276B2 (ja) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎感染の治療方法

Also Published As

Publication number Publication date
CO2020005135A2 (es) 2020-05-15
BR112020007476A2 (pt) 2020-10-27
US11273173B2 (en) 2022-03-15
IL274040A (en) 2020-06-30
CN111372593B (zh) 2024-03-19
RS64001B1 (sr) 2023-03-31
PL3684377T3 (pl) 2023-04-17
RU2020116369A3 (fr) 2022-02-28
CA3078960A1 (fr) 2019-04-25
JP2021500025A (ja) 2021-01-07
US20230000895A1 (en) 2023-01-05
SG11202003488WA (en) 2020-05-28
MA50264A (fr) 2020-07-29
EP4197544A1 (fr) 2023-06-21
WO2019079781A2 (fr) 2019-04-25
US20200338109A1 (en) 2020-10-29
PH12020550591A1 (en) 2021-03-01
CR20200163A (es) 2020-11-02
US11052104B2 (en) 2021-07-06
PT3684377T (pt) 2023-01-31
US20200171069A1 (en) 2020-06-04
US20210283164A1 (en) 2021-09-16
AU2018351649A1 (en) 2020-04-23
JP2023171403A (ja) 2023-12-01
LT3684377T (lt) 2023-03-10
PE20220561A1 (es) 2022-04-13
US20200338108A1 (en) 2020-10-29
IL282881A (en) 2021-06-30
HRP20230023T1 (hr) 2023-03-17
JP7353276B2 (ja) 2023-09-29
EP3684377A4 (fr) 2020-12-16
RU2020116369A (ru) 2021-11-22
CN111372593A (zh) 2020-07-03
US10799524B2 (en) 2020-10-13
ES2936863T3 (es) 2023-03-22
HUE061122T2 (hu) 2023-05-28
KR20200083494A (ko) 2020-07-08
FI3684377T3 (fi) 2023-01-31
US11052105B2 (en) 2021-07-06
SI3684377T1 (sl) 2023-05-31
IL274040B1 (en) 2024-04-01
EP3684377B1 (fr) 2022-12-07
CL2020001061A1 (es) 2020-10-30
DK3684377T3 (da) 2023-02-13
EP3684377A2 (fr) 2020-07-29
MX2020004060A (es) 2020-07-21
WO2019079781A3 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
MA50264B1 (fr) Méthodes de traitement des infections de type hépatite b
MA50278A (fr) Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
HK1248681A1 (zh) 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物
MX2021006635A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
MA42951A (fr) Méthode de réacheminement de lymphocytes t pour le traitement d'une infection par le vih
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA50267A (fr) Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
MD3261720T2 (ro) Anticorpi anti-Tau și utilizările acestora
MA45496A (fr) Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
BR112021011858A2 (pt) Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite b
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
MA52151A (fr) Molécule d'acide nucléique pour la réduction de l'arnm de papd5 et de papd7 pour le traitement d'une infection par l'hépatite b
EA202190528A1 (ru) КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA55720A (fr) Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
MX2021004580A (es) Compuestos de heteroarilcarboxamida de 5 miembros para el tratamiento del vhb.
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique